Palmidrol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Palmidrol
DrugBank Accession Number
DB14043
Background

A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).

Type
Small Molecule
Groups
Experimental, Nutraceutical
Structure
Thumb
Weight
Average: 299.4919
Monoisotopic: 299.282429433
Chemical Formula
C18H37NO2
Synonyms
  • Hydroxyethylpalmitamide
  • Monoethanolamine palmitic acid amide
  • N-(2-Hydroxyethyl)palmitamide
  • N-hexadecanoylethanolamine
  • N-palmitoylethanolamine
  • Palmidrol
  • palmidrolum
  • Palmitamide MEA
  • Palmitic acid monoethanolamide
  • Palmitinsaeure-beta-hydroxyethylamid
  • Palmitoyl ethanolamide
  • Palmitoyl-EA
  • Palmitoylethanolamide

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when Palmidrol is combined with 1,2-Benzodiazepine.
AcebutololThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Acetophenazine.
AclidiniumThe risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Palmidrol.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Palmidrol.
AgomelatineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Palmidrol is combined with Alimemazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Palmidrol is combined with Almotriptan.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Palmdrol prodes

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as carboximidic acids. These are organic acids with the general formula RC(=N)-OH (R=H, organic group).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboximidic acids and derivatives
Sub Class
Carboximidic acids
Direct Parent
Carboximidic acids
Alternative Parents
Propargyl-type 1,3-dipolar organic compounds / Alkanolamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic acyclic compound / Alkanolamine / Carboximidic acid / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
N-(long-chain-acyl)ethanolamine, endocannabinoid, N-(saturated fatty acyl)ethanolamine (CHEBI:71464) / N-acyl ethanolamines (endocannabinoids) (LMFA08040013)
Affected organisms
Not Available

Chemical Identifiers

UNII
6R8T1UDM3V
CAS number
544-31-0
InChI Key
HXYVTAGFYLMHSO-UHFFFAOYSA-N
InChI
InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
IUPAC Name
N-(2-hydroxyethyl)hexadecanamide
SMILES
CCCCCCCCCCCCCCCC(=O)NCCO

References

General References
Not Available
Human Metabolome Database
HMDB0002100
KEGG Drug
D08328
KEGG Compound
C16512
ChemSpider
4509
BindingDB
29083
RxNav
2001986
ChEBI
71464
ChEMBL
CHEMBL417675
ZINC
ZINC000008035017
Wikipedia
Palmitoylethanolamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentPain, Chronic1
2CompletedTreatmentGilles de la Tourette's Syndrome1
2RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
2Unknown StatusTreatmentGilles de la Tourette's Syndrome1
2, 3Not Yet RecruitingTreatmentDermatitis, Dermatitis Atopic1
Not AvailableCompletedBasic ScienceAmyotrophic Lateral Sclerosis (ALS)1
Not AvailableCompletedTreatmentChronic Pelvic Pain / Endometriosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00136 mg/mLALOGPS
logP5.74ALOGPS
logP4.98ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)15.46ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity90.09 m3·mol-1ChemAxon
Polarizability40.05 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0w29-7179000000-22766d934944105dccf9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-9130000000-c6d2bfc2e68da1f5b0d2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-9410000000-d078025cabaaf62c59b9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-1090000000-5224a67dd0daaea79191
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-01ot-5090000000-dd9396934201d60f5af2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9010000000-d5bf936e945bfc965dfe

Drug created on May 22, 2018 17:59 / Updated on February 21, 2021 18:54